Overview

• The BROADWAY phase 3 trial demonstrated that Obicetrapib reduced LDL cholesterol levels by 32.6% and lipoprotein(a) levels by 33.5% after 12 weeks, compared to placebo.
• The trial included 2,530 high-risk cardiovascular patients across multiple countries, with participants randomized to receive Obicetrapib or placebo alongside standard lipid-lowering therapy.
• Obicetrapib's hydrophilic design avoids off-target effects seen in earlier CETP inhibitors, addressing safety concerns that hindered previous drugs in this class.
• The drug was well tolerated, with adverse event rates comparable to placebo, and no significant differences in severity between the groups.
• A large, long-term outcomes trial is currently underway to evaluate whether Obicetrapib can reduce cardiovascular events in high-risk patients.